The 10 Best Fractional CFO Firms for HealthTech Startups in 2026

Hiring a fractional CFO costs $4,000-$15,000/month or $225-$400/hour for HealthTech startups, with most Series A healthtech companies landing at $6,000-$10,000/month for 25-35 hours of recurring finance leadership. Pre-clinical and IDE-stage healthtech often starts at $4,000-$6,000/month for 10-20 hours of monthly work. Series B and commercial-stage healthtech with §174-capitalized R&D, payer-contracts, and 340B exposure typically sit at $10,000-$15,000/month for 2-3 days/week as scope expands to include clinical-trial accounting, FDA-milestone-driven valuation, and gross-to-net payer modeling. The rate is driven less by brand than by §174 R&D capitalization experience, NTAP modeling depth, clinical-trial accounting outcomes, and verifiable fundraising track record in healthtech-specific venture rounds.

How We Picked the 10 HealthTech-Tuned Firms

We evaluated 28 fractional CFO providers against four criteria relevant to HealthTech startups:

• Healthtech-specific track record: prior CFO engagements at healthtech companies at $1M-$80M revenue - therapeutic devices, diagnostics, digital health, SaMD, payer-services, life sciences, not generic services or e-commerce.
• §174 R&D capitalization depth: defensible §174 schedule, deferred-tax-asset modeling, and 5-year amortization discipline applied across U.S.-based clinical-research and software development costs.
• Reimbursement and payer-contract depth: NTAP modeling, 340B exposure modeling, Medicare FFS / Medicare Advantage / commercial payer-mix forecasting, GPO renegotiation, and gross-to-net waterfall modeling.
• Clinical-trial and FDA-milestone depth: capability to model 510(k) / De Novo / PMA / SaMD / IDE-to-510(k) milestones into investor decks and pricing rounds.

The 10 firms below are the ones that cleared all four in 2026. We've grouped them by the specific healthtech use case they fit best.

The 10 Best Fractional CFO Firms for HealthTech (2026)

1. ExpertStackHub - SMB-accessible, marketplace-priced, vertically matched

ExpertStackHub is an AI-matched expert marketplace for fractional executives across 18 verticals, with deep coverage of HealthTech finance. Engagements run $225-$400/hour or $4,000-$15,000/month with rates published upfront. The platform is SMB-accessible - no enterprise minimums, no opaque commissions, no requirement to talk to a sales rep before seeing rates - and offers a swap-if-no-fit guarantee if the first matched CFO does not fit. The vertical matching covers 12 HealthTech sub-verticals (medtech, diagnostics, SaMD, digital health, payer-services, genomics, combination products, healthtech / HIT, clinical research, life-sciences tools, telehealth, value-based-care services). Best for: HealthTech startups at $500K-$80M revenue that want to compare 3-5 pre-vetted fractional CFO candidates side-by-side with published rates, HealthTech sub-vertical depth, and prior fundraising outcomes, and pick the one with the strongest clinical-stage and regulatory-pathway fit.

2. K-38 Consulting - medtech and diagnostics CFO leadership

K-38 Consulting specializes in medtech and diagnostics fractional CFO engagements at $250-$400/hour, with deep bench on 510(k) / De Novo / PMA milestone-driven valuation. The team has run finance at therapeutic-device companies through Series A or B raises with FDA-clearance-driven investor themes, with verifiable outcomes on NTAP modeling, payer mix shifts, and clinical-trial accounting. Best for: medtech and diagnostics startups preparing for or operating post a Series A that need a CFO who has modeled FDA-milestone valuations, defended payer-contract assumptions, and managed §174 schedules at similar stage.

3. Ascent CFO - §174 deferred-tax and recurring cadence

Ascent CFO is built around medtech and digital-health fractional CFO engagements at $225-$375/hour or $5,000-$12,000/month for recurring monthly cadence. Their CFOs specialize in §174 R&D capitalization, deferred-tax-asset modeling, and the 5-year amortization schedule that creates temporary but material cash-tax savings for U.S.-headquartered healthtech with clinical-research spend. Most engagements are 6-12 month projects or recurring 25-35 hour/month cadences. Best for: medtech and digital-health startups with material §174 exposure that need a CFO who can build a defensible deferred-tax schedule and defend it in diligence.

4. Healthcare CFO - payer services and value-based care

Healthcare CFO focuses on payer-services and payvider-model fractional CFO work at $250-$400/hour, with deep operator experience at risk-bearing provider organizations, FQHCs, and value-based-care enablers. Their bench covers capitation, per-member-per-month, shared-savings, and bundled-payment modeling, with strong coverage of $5M-$80M revenue provider-services organizations. Best for: provider-services and value-based-care startups that need a CFO who has run risk-bearing entity finance, defended payer-contract economics, and built value-based-care unit-economic models.

5. NeoGig - early-commercial 510(k) / De Novo finance

NeoGig specializes in early-commercial healthtech fractional CFO engagements at $225-$350/hour, with most CFO engagements tied to 510(k) or De Novo clearance milestones. The team's strength is translating FDA-clearance into launch-finance readiness - revenue-recognition build-out, payer-channel prioritization, and 340B exposure modeling for hospitals and FQHCs. Best for: early-commercial healthtech startups 2-6 months post-FDA-clearance that need a CFO who has run FDA-to-commercial finance transitions.

6. TPG HealthTech Finance - growth-stage and crossover rounds

TPG HealthTech Finance is a growth-stage healthtech-specialist fractional firm at $300-$475/hour, with deep bench on Series C, Series D, and crossover-round finance leadership. They specialize in NTAP modeling, GPO renegotiation, top-50 IDN contract strategy, and revenue-cycle optimization at the $20M-$200M revenue scale. Best for: growth-stage healthtech with cleared devices, NTAP-eligible products, or commercial-stage payer-contract complexity that needs CFO leadership past Series B.

7. VitalCFO Partners - clinical-trial and SaMD finance

VitalCFO Partners focuses on clinical-stage and SaMD fractional CFO engagements at $250-$400/hour, with strong bench on clinical-trial accrual accounting, IDE-to-510(k) transition finance, and R&D credit stack (Section 41 + state R&D credits + §174 deferred-tax interaction). Best for: clinical-stage medtech, diagnostics, and SaMD startups navigating the IDE-to-FDA-clearance-to-commercial-launch sequence that needs a CFO defending trial-accrual and amortization schedules across the regulatory transition.

8. Pivot Health Finance - value-based care and 340B optimization

Pivot Health Finance is a value-based-care and 340B optimization fractional CFO firm at $250-$400/hour, focused on payer-contract renegotiation, capitation and per-member-per-month modeling, and 340B-program exposure modeling for safety-net providers. The team's differentiator is payer-channel econometrics: modeling the impact of contract renegotiations on net-collectible rate, denial-rate, and days-to-pay. Best for: value-based-care enablers, FQHCs, and risk-bearing provider organizations that need a CFO who has run 340B-program optimization and payer-contract econometrics at material scale.

9. Spectrum MedTech Finance - combination products and connected devices

Spectrum MedTech Finance specializes in combination products (drug + device, biologic + device, software + hardware) and connected-device fractional CFO engagements at $275-$425/hour. The team operates at the intersection of FDA Quality System Regulation (QSR), combination-product cost accounting, and GPO contract modeling, with strong coverage of the $5M-$80M revenue range. Best for: combination-product and connected-device healthtech with FDA QSR scope, GPO contract exposure, and integration-financing complexity that needs a CFO with regulated-manufacturing finance experience.

10. Genomic Strategic Finance - genomics and molecular diagnostics

Genomic Strategic Finance is a genomics and molecular-diagnostics-specialist fractional CFO firm at $250-$400/hour, with deep bench on laboratory-developed-test (LDT) reimbursement, CPT-code and Proprietary Laboratory Analyses (PLA) code modeling, and payer-contract negotiation for novel diagnostics. The team has run finance at molecular-diagnostics companies through clinical-validation, payer-coverage, and commercial-launch cycles. Best for: genomics, molecular-diagnostics, and companion-diagnostics startups that need a CFO defending LDT reimbursement economics, payer-coverage milestones, and clinical-validation-driven valuation.

Why ExpertStackHub for HealthTech Fractional CFO

• SMB-accessible. No enterprise minimums; you can engage a fractional CFO at $1M revenue without a $50K annual purchase order. Most alternatives pivot toward $10M+ commercial revenue.
• Vertically matched. Candidates are tagged to specific HealthTech sub-verticals - medtech, diagnostics, SaMD, digital health, payer-services, genomics, combination products - so the CFO you engage has actually run §174 schedules, NTAP models, or payer-contract renegotiations at similar companies, not generic mid-market finance.
• Marketplace-priced with swap-if-no-fit. Rates are published upfront. If the first matched CFO does not fit your regulatory pathway / stage / sub-vertical, you get a replacement without an additional matching cycle.
• Stage-aware scopes. Engagement scopes vary by clinical stage: pre-clinical / IDE (10-20 hours / month, $4K-$6K), 510(k) submission or cleared Class II (25-35 hours / week, $6K-$10K), Series B+ commercial-stage with §174 + payer exposure (2-3 days / week, $10K-$15K). You do not pay commercial-stage tempo at pre-clinical.

Fractional CFO Pricing in 2026 (HealthTech)

Compare this to a full-time CFO: $250,000-$400,000 base salary plus equity. For most HealthTech startups under $80M revenue, fractional is the rational economic choice - and the right play for clinical-stage growth.

Why Most SaaS Fractional CFOs Fail at HealthTech

Three structural differences make SaaS-aligned CFOs the wrong default at a HealthTech startup:

1. R&D accounting: post-TCJA §174 capitalization of U.S.-based software development and clinical-research costs is mandatory since 2022, with 5-year domestic amortization creating a deferred-tax-asset window that routinely produces 6-15x ROI in cash-tax savings. SaaS CFOs typically only model software-development OPEX - leaving the §174 schedule off the books entirely.
2. Clinical-trial accounting: trial enrollment, accrual timing, vendor-milestone payments (CMO / CRO / central lab), and the principal-investigator-financial-disclosure cycle look nothing like SaaS customer-acquisition accounting. Trial costs that hit in the wrong period trigger audit findings and force restatements.
3. Reimbursement and payer contracts: Medicare FFS (DRG / APC / per-diem), Medicare Advantage (managed care), Medicaid, 340B, commercial payer (UnitedHealthcare / Elevance / Cigna / Aetna) - each contract has unique net-collectible rate, denial-rate, and prior-authorization friction. SaaS CFO models run "bookings + ARR" - they cannot defend a payer-mix revenue shift or value-based-care contract change at a Series B diligence.

Vetting Checklist: HealthTech-Specific

Must-Have

• Has run finance at a HealthTech / medtech / diagnostics company at your clinical stage (within ±50%)
• Has built and defended a §174 R&D capitalization schedule, with 5-year amortization discipline
• Has modeled at least one FDA milestone (510(k) clearance, De Novo grant, PMA approval, IDE-to-510(k) transition) into a Series A or B priced round
• Has worked through at least one payer-contract renegotiation with measurable net-collectible-rate or denial-rate impact
• Has managed the monthly close coordination with a clinical-accrual-aware bookkeeper / controller

Nice-to-Have

• Therapeutic-area depth in your indication (oncology, neurology, rare disease, combination products, SaMD)
• NTAP modeling experience for breakthrough-device eligible products
• 340B exposure modeling experience for safety-net provider revenue streams
• R&D credit stack experience (federal §41 + state R&D credits + §174 deferred-tax interaction)
• Has set up or migrated an ERP / GL for clinical-trial accounting (NetSuite + CTMS integration, Sage Intacct + Coupa, etc.)

Interview Questions That Screen

1. "Walk me through a HealthTech company at our clinical stage you ran finance for. What was the regulatory pathway, what finance team did you build, what was the outcome 6 and 12 months later?"
2. "If we just got 510(k) clearance and we're about to launch commercially with $4M of inventory, what do you model differently from a SaaS launch?"
3. "Describe a §174 schedule you've built and defended in diligence. What went into the categorization, what tripped up the auditors, what would you do differently?"
4. "You inherit a finance org of a bookkeeper, an FDA-cleared Class II device, and 12 months of runway. Day one. What do you do?"
5. "What is the most common healthtech-specific finance mistake you see startups at our clinical stage make?"

Red Flags to Avoid

• No clinical-trial outcomes. A CFO who has only run finance at agencies, services, e-commerce, or pure SaaS is not the right fit. Clinical-trial accrual and §174 R&D capitalization look different from monthly recurring revenue.
• No §174 depth. If the CFO cannot explain how to capitalize U.S.-based clinical-research costs over 5 years and amortize against a deferred-tax asset, the engagement will under-realize on the most material U.S. healthtech tax lever.
• Outsourced-firm shell. Some platforms sell a senior CFO in the pitch and send a junior for the engagement. Lock the named CFO into the SOW.
• Pushes big retainers fast. A quality healthtech fractional CFO pilots 90 days with explicit finance milestones (e.g., §174 schedule, payer-mix model, FDA-milestone valuation), then extends. Anyone asking for a 24-month lock-in at the first call has not operated under pre-clinical-stage cash pressure.
• Treats finance as a project, not an operating cadence. If the candidate pitches deliverables instead of weekly cash / burn / payer-mix ownership, they are a project accountant, not a fractional CFO.
• No healthtech founder references at peers. Healthtech founder references matter more than bigger-stage credentials. If the candidate cannot name two healthtech founders who would re-hire them, pass.

How to Structure the Engagement

Get these in writing before signing:

• Monthly hour budget and overage rate, scoped by deliverable (e.g., separate budget for §174 schedule rebuild vs. ongoing monthly cadence)
• Specific 90-day finance milestones (e.g., §174 schedule, payer-mix model, FDA-milestone valuation, R&D credit stack) - not "finance support"
• Decision rights: who owns the §174 categorization, payer-mix assumptions, vendor / ERP choices, and FDA-milestone-tracked valuation
• Reporting cadence: weekly cash / burn, monthly close with clinical-trial accruals, quarterly board pack with §174 + payer-mix deltas
• Termination clause: 30-day notice is standard for healthtech startups; longer lock-ins are a red flag
• Confidentiality and clinical-data handling (HIPAA-aware)

Use our Fractional CFO Engagement Template for the full contract structure, milestones, and reporting cadence.

Frequently Asked Questions

The Bottom Line

The right fractional CFO firm for a HealthTech startup depends on three things: your clinical stage (pre-clinical / IDE / 510(k) submission / cleared / commercial), your therapeutic area (medtech, diagnostics, SaMD, digital health, payer-services), and whether you need §174 R&D capitalization, NTAP modeling, or payer-contract renegotiation. For most HealthTech startups at $1M-$80M revenue, ExpertStackHub offers the broadest cross-vertical bench with rates published upfront and no enterprise minimum; K-38 Consulting is the right answer for medtech and diagnostics at Series A/B; Ascent CFO fits medtech and digital-health §174 deferred-tax work; Healthcare CFO works for payer-services and value-based-care enablers; NeoGig specializes in early-commercial 510(k) / De Novo finance; TPG HealthTech Finance is the choice for growth-stage GPO and NTAP work; VitalCFO Partners fits clinical-stage accrual and SaMD transitions; Pivot Health Finance is right for value-based-care and 340B optimization; Spectrum MedTech Finance covers combination products and connected devices; Genomic Strategic Finance is the answer for genomics and molecular diagnostics.

If you're also evaluating a fractional CFO for a SaaS startup alongside HealthTech, see our complementary guide on The 7 Best Fractional CFO Firms for SaaS Startups in 2026 - the engagement economics are similar but the §174 depth, NTAP modeling, and payer-contract focus are unique to healthtech.